DCGI approval for Sputnik V vaccine expected soon: Dr Reddy’s

Dr Reddy’s Laboratories expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said.

“We expect to get approval in the next few weeks. It is a two-dose vaccine. You take the first dose on day zero and the second one on day 21. The peak immunity develops somewhere between day 28 to day 42.

So, it is a two-dose vaccine and we expect it to be available in the next few weeks,” Deepak Sapra, the company’s CEO, APIs and Services, said.

Sapra, who was speaking in a webinar, was asked as to how soon Sputnik would be available and whether it is a one dose or two doses vaccine.

Dr Reddy’s has partnered with the Russia Direct Investment Fund (RDIF) to bring the Sputnik V vaccine to India and other countries, he said.

Observing that trials of the vaccine have been conducted in Russia, India, the UAE and others, he said the vaccine demonstrated efficacy of 91.6 per cent as published in the reputed journal Lancet.

The data on trials is currently with the Indian regulator and the company expects it to get approved in the next few weeks, he said

Related Posts

Licences of 20 medical stores suspended after inspections

Drug Control Department inspects 120 medical stores; 32 NDPS cases and 63 arrests recorded in 2026 so far The district administration has intensified action against illegal drug sale and distribution,…

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

NEW DELHI: Global investment firm Bain Capital has divested nearly a 1 per cent stake in Emcure Pharmaceuticals for over Rs 289 crore through open market transactions, according to the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert

Civil society group SAM calls for greater transparency involving clinical trials

Civil society group SAM calls for greater transparency involving clinical trials

Different packaging, typos expose fake Mounjaro racket

Different packaging, typos expose fake Mounjaro racket